​

Psychedelic clinical research & trials is a topic in the health domain with significant developments in policy, regulation, and public health impact.

Key developments include definium reports positive phase 3 results for single-dose dt120 in generalized anxiety disorder, xenon pharmaceuticals pauses depression drug trials over neuropsychiatric side effects, fda seeks public input on clinical trial design for ibogaine drug products, among other significant events and policy changes.

Source: Geo Health Space